tradingkey.logo

Renovaro Inc

RENB
View Detailed Chart
1.420USD
0.000
Market hours ETQuotes delayed by 15 min
251.90MMarket Cap
LossP/E TTM

Renovaro Inc

1.420
0.000
Intraday
1m
30m
1h
D
W
M
D

Today

0.00%

5 Days

0.00%

1 Month

0.00%

6 Months

+389.32%

Year to Date

+69.96%

1 Year

+127.05%

View Detailed Chart

TradingKey Stock Score of Renovaro Inc

Currency: USD Updated: 2025-09-30

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Despite strong stock market performance and technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Renovaro Inc's Score

Industry at a Glance

Industry Ranking
259 / 505
Overall Ranking
431 / 4713
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Renovaro Inc Highlights

StrengthsRisks
Renovaro Inc. specializes in cancer diagnostics and therapeutics powered by artificial intelligence (AI). The Company operates through two subsidiaries: Renovaro Biosciences, Inc. (Renovaro Biosciences) and Renovaro Cube. Renovaro Biosciences is a biotechnology company intending to develop advanced allogeneic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) infections. Renovaro Cube is an AI-driven healthcare technology company focusing on the earliest possible detection of cancer and its recurrence. Renovaro Cube has developed an AI platform that analyzes genetics using Explainable AI to provide earlier and more accurate cancer diagnosis. This platform uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.
Undervalued
The company’s latest PE is -5.82, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 65.41M shares, increasing 6.49% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 4.92M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.33.

Renovaro Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Renovaro Inc Info

Renovaro Inc. specializes in cancer diagnostics and therapeutics powered by artificial intelligence (AI). The Company operates through two subsidiaries: Renovaro Biosciences, Inc. (Renovaro Biosciences) and Renovaro Cube. Renovaro Biosciences is a biotechnology company intending to develop advanced allogeneic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) infections. Renovaro Cube is an AI-driven healthcare technology company focusing on the earliest possible detection of cancer and its recurrence. Renovaro Cube has developed an AI platform that analyzes genetics using Explainable AI to provide earlier and more accurate cancer diagnosis. This platform uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.
Ticker SymbolRENB
CompanyRenovaro Inc
CEOMr. David Weinstein
Website
KeyAI